Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Affimed Community
NasdaqGM:AFMD Community
1
Narratives
written by author
0
Comments
on narratives written by author
6
Fair Values set
on narratives written by author
Create a narrative
Affimed
Popular
Undervalued
Overvalued
Community Investing Ideas
Affimed
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
ASH 2024 Updates Will Validate Clinical Proof Of Concept
Key Takeaways Positive clinical results and safety profile of NK cell engagers boost potential revenue and adoption, enhancing net margins and efficacy. Strategic partnerships and capitalization efforts aim to improve financial stability and investor confidence, supporting long-term operations and earnings growth.
View narrative
US$12.91
FV
93.9% undervalued
intrinsic discount
44.36%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
6 days ago
author updated this narrative
Your Valuation for
AFMD
AFMD
Affimed
Your Fair Value
US$
Current Price
US$0.83
91.4% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-119m
50m
2015
2018
2021
2024
2025
2027
2030
Revenue €50.0m
Earnings €10.2m
Advanced
Set Fair Value